Limitless Potential. Precision Design. Enduring Impact.

HARNESSING THE UNLIMITED, SELF-RENEWING POTENTIAL OF iPSCs TO DRAMATICALLY AND POSITIVELY TRANSFORM THE LIVES OF PATIENTS SUFFERING FROM LIFE-THREATENING CANCERS

ABOUT US

We develop transformative, allogeneic, iPSC-derived NK and T cell therapies to create products for the treatment of both hematological and solid tumor malignancies with significant unmet medical need.

Learn more ABOUT Century

OUR SCIENCE

Our engineered, iPSC-derived allogeneic cell therapy platform was designed to yield therapies that overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies.

Learn more about our approach

NEWS & EVENTS

2021/09

Century Therapeutics Announces Its Addition to the Russell 2000® Index
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® Index as a part
Read more
2021/08

Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221M June 30, 2021 cash, cash equivalents, and marketable securities of $440M PHILADELPHIA, Aug.
Read more

CAREERS

We are seeking new team members motivated to advance the course of cancer care.

Discover our open positions

Media

Contact Us
© Century Therapeutics 2021 | Legal